Pharmaceuticals - BRICS

  • BRICS
  • The projected revenue for the Pharmaceuticals market in 2024 is expected to reach a staggering US$161.30bn.
  • Within this market, the largest market is Oncology Drugs, which is projected to have a market volume of US$28.15bn in 2024.
  • Looking ahead, the revenue is anticipated to exhibit an annual growth rate (CAGR 2024-2029) of 5.53%, leading to a market volume of US$211.10bn by 2029.
  • In terms of global comparison, United States is expected to generate the highest revenue, with a projected amount of US$630.30bn in 2024.
  • It is worth noting that the BRICS countries, including Brazil, Russia, India, China, and South_Africa, play a significant role in the Pharmaceuticals market.
  • In Brazil, the pharmaceutical market is experiencing a rise in demand for generic drugs due to their affordability and accessibility.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The demand for Pharmaceuticals in BRICS is increasing due to various factors such as population growth, urbanization, and rising income levels.

Customer preferences:
In Brazil, there is a growing demand for generic drugs due to their affordability, and the government's efforts to promote their use. Russia is seeing a shift towards natural and herbal remedies, while in India, traditional medicine is still popular. China is experiencing a rise in demand for high-end pharmaceuticals due to an aging population and increasing disposable income. South Africa is seeing a growing demand for chronic disease medication due to the high prevalence of diseases such as HIV/AIDS and tuberculosis.

Trends in the market:
In Brazil, the pharmaceutical market is expected to grow due to an aging population and higher healthcare spending. Russia is experiencing a shift towards locally produced drugs, and the government is investing in the development of the domestic pharmaceutical industry. India is becoming a hub for contract manufacturing and research due to its low-cost advantage. China is expected to become the world's second-largest pharmaceutical market, driven by an aging population and increasing healthcare spending. South Africa is seeing a growing demand for generic drugs due to their affordability.

Local special circumstances:
Brazil has a complex regulatory environment that can make it difficult for foreign companies to enter the market. Russia has a high level of bureaucracy and corruption, which can make it challenging for foreign companies to do business. India has a large population and a fragmented market, which can make it difficult for companies to achieve economies of scale. China has a complex regulatory environment and intellectual property rights issues that can make it challenging for foreign companies to enter the market. South Africa has a high burden of disease and a large uninsured population, which can make it challenging for companies to sell high-priced drugs.

Underlying macroeconomic factors:
The BRICS countries are experiencing economic growth, which is driving demand for healthcare services. Rising incomes and urbanization are also contributing to the growth in demand for pharmaceuticals. However, each country has its own unique challenges, such as regulatory issues, corruption, and high disease burden, which can impact the growth of the pharmaceutical market. Overall, the BRICS countries present significant opportunities for pharmaceutical companies due to their large populations and growing economies.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)